首页|重构本草——白芍

重构本草——白芍

扫码查看
通过对古籍文献记载、中医药现代研究成果的梳理,结合中医学及中药学等学科领域内知名专家学者的认识及临床应用经验,归纳出白芍:功效主要为养血敛血、柔肝止痛、平抑肝阳.症靶为腹痛、肌肉痉挛、胁痛.现代药理学研究揭示,白芍及其有效成分白芍总苷具有抗炎、解痉、镇痛、抑菌、通便、缓解急性肝损伤以及调节免疫等功效.白芍及其主要成分白芍总苷的长期毒性实验,未发现对人体和动物的毒性,安全范围大.临床使用剂量为6~120g,内服时应根据不同疾病或同一疾病的不同阶段进行辨证使用,并积极探索白芍用量与症靶的量效关系构建.
Reconstruction of Chinese materia medica-debark peony root
Through the investigation of ancient books and the sorting of the modern research achievements of traditional Chinese medicine,combined with the understanding and application experience of well-known experts and scholars in desciplinary fields such as traditional Chinese medicine clinical medicine and science of Chinese materia medica,it is concluded that debark peony root mainly has the effects of nourishing and constraining blood,softening liver for relieving pain,and calming liver yang.The symptom targets are abdominal pain,muscle spasm,and hypochondriac pain.Modern pharmacological studies have found that debark peony root and its active ingredient,namely total glucosides of debark peony root have the effects of anti-inflammatory,spasmolysis,analgesia,bacteriostasis,defaecation,alleviating acute liver injury,and immunomodulatory.Long-term toxicity experiments of debark peony root and its main component,total glucosides of debark peony root,do not find any toxicity to humans or animals,and the safety range is large.The clinical dose is 6-120 g.When taken orally,it should be used dialectically according to different diseases or different stages of the same disease,and the construction of dose-effect relationship between the dosage of debark peony root and the symptom target should be explored actively.

debark peony rootsymptom targetreconstruction of Chinese materia medicaclinical verification

赵旌屹、马凯乐、张伟、苟筱雯、田佳星、宋斌、王涵、李敏

展开 >

中国中医科学院广安门医院,北京 100053

甘肃中医药大学基础医学院,兰州 730000

遵义市第一人民医院,贵州遵义 563000

北京中医药大学,北京 100029

展开 >

白芍 症靶 重构本草 临床回归

中国中医科学院科技创新工程项目资助北京中医药大学壶天客座教授科研启动经费资助

CI2021A016062023-XJ-KYQD-006

2024

长春中医药大学学报
长春中医药大学

长春中医药大学学报

CSTPCD
影响因子:0.916
ISSN:1007-4813
年,卷(期):2024.40(1)
  • 2
  • 21